Cargando…
Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials have examined the efficacy of trastuzumab in this setting. This prospective obser...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276464/ https://www.ncbi.nlm.nih.gov/pubmed/35758368 http://dx.doi.org/10.1097/MD.0000000000029371 |